Predicted Impact of COVID-19 on Neglected Tropical Disease Programs and the Opportunity for Innovation.
Toor J., Adams ER., Aliee M., Amoah B., Anderson RM., Ayabina D., Bailey R., Basáñez M-G., Blok DJ., Blumberg S., Borlase A., Rivera RC., Castaño MS., Chitnis N., Coffeng LE., Crump RE., Das A., Davis CN., Davis EL., Deiner MS., Diggle PJ., Fronterre C., Giardina F., Giorgi E., Graham M., Hamley JID., Huang C-I., Kura K., Lietman TM., Lucas TCD., Malizia V., Medley GF., Meeyai A., Michael E., Porco TC., Prada JM., Rock KS., Le Rutte EA., Smith ME., Spencer SEF., Stolk WA., Touloupou P., Vasconcelos A., Vegvari C., de Vlas SJ., Walker M., Hollingsworth TD.
Due to the COVID-19 pandemic, many key neglected tropical disease (NTD) activities have been postponed. This hindrance comes at a time when the NTDs are progressing towards their ambitious goals for 2030. Mathematical modelling on several NTDs, namely gambiense sleeping sickness, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases (STH), trachoma, and visceral leishmaniasis, shows that the impact of this disruption will vary across the diseases. Programs face a risk of resurgence, which will be fastest in high-transmission areas. Furthermore, of the mass drug administration diseases, schistosomiasis, STH, and trachoma are likely to encounter faster resurgence. The case-finding diseases (gambiense sleeping sickness and visceral leishmaniasis) are likely to have fewer cases being detected but may face an increasing underlying rate of new infections. However, once programs are able to resume, there are ways to mitigate the impact and accelerate progress towards the 2030 goals.